title: Antitumor Effects of Eribulin Mesylate in Gemcitabine-resistant Pancreatic Cancer Cell Lines.
abstract: One reason of poor survival rate of patients with pancreatic cancer is the development of chemoresistance. The aim of the present study was to investigate the effects of eribulin mesylate in gemcitabine-refractory advanced pancreatic cancer cell lines.
  
  
  
  Three human pancreatic cancer cell lines (AsPC-1, Panc-1, and SUIT-2) and human pancreatic endoderm (hPE) cells were used to evaluate the antitumor effects of gemcitabine and eribulin mesylate. Cell viability after treatment of cells with different concentrations of gemcitabine and eribulin mesylate was evaluated using water-soluble tetrazolium salts (WST) assays; cytotoxic effects were evaluated on the basis of morphological changes to cells.
  
  
  
  Gemcitabine had no effect on cell viability of AsPC-1 nor Panc-1 cells, whereas gemcitabine reduced cell viability of SUIT-2 cells in a dose-dependent manner. Eribulin mesylate significantly reduced cell viability of both AsPC-1 and Panc-1 cells (p<0.001 and p=0.002, respectively), but had no effect on hPE cells. Microscopic examination of AsPC-1 and Panc-1 cells after treatment with eribulin mesylate revealed morphological changes that included cell shrinkage, membrane blebbing, and fragmentation of the cells after drug exposure, and these were concentration-dependent effects.
  
  
  
  The findings of the present study suggest that eribulin mesylate may be a promising potential anticancer drug for gemcitabine-refractory advanced pancreatic cancer.
authors: Department of Surgery, Kochi Medical School Hospital, Kochi, Japan.
authors: Yuka
authors: Y
authors: Takezaki
authors: Department of Surgery, Kochi Medical School Hospital, Kochi, Japan tsutomun@kochi-u.ac.jp.
authors: Tsutomu
authors: T
authors: Namikawa
authors: Center for Innovative and Translational Medicine, Kochi Medical School Hospital, Kochi, Japan.
authors: Tsuyoshi
authors: T
authors: Koyama
authors: Department of Surgery, Kochi Medical School Hospital, Kochi, Japan.
authors: Eri
authors: E
authors: Munekage
authors: Department of Surgery, Kochi Medical School Hospital, Kochi, Japan.
authors: Masaya
authors: M
authors: Munekage
authors: Cancer Treatment Center, Kochi Medical School Hospital, Kochi, Japan.
authors: Hiromichi
authors: H
authors: Maeda
authors: Department of Surgery, Kochi Medical School Hospital, Kochi, Japan.
authors: Hiroyuki
authors: H
authors: Kitagawa
authors: Department of Surgery, Kochi Medical School Hospital, Kochi, Japan.
authors: Kazuhiro
authors: K
authors: Hanazaki
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005663:Furans / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000494:pharmacology / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000093542:Gemcitabine; D000095662:Polyether Polyketides
chemical_list: D000970:Antineoplastic Agents; D003841:Deoxycytidine; D005663:Furans; D007659:Ketones; D000093542:Gemcitabine; C490954:eribulin; D000095662:Polyether Polyketides
keywords: Eribulin mesylate; advanced pancreatic cancer; chemotherapy; gemcitabine